Unlike other lipid testing companies that are focused on the primary screening market for CVD, their proprietary testing technology allows for the ongoing monitoring of a patient's disease and precise determination of the most appropriate pharmaceutical alternatives. They can provide unique, personalized treatment options to patients with dyslipidemia to determine the efficacy of lipid adjusting drugs in most cases within the first 6 weeks of treatment. Competing methods usually need 6 months.